Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today reported its financial results for the quarter ended March 31, 2020 and provided a business update.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that it has reached a new agreement with Medigene AG ("Medigene") in relation to Phio Pharmaceuticals' previously announced research collaboration in August 2019 with the Helmholtz Zentrum München to design and develop novel candidates for the use of INTASYL™ compounds in adoptive cell therapy to enhance immune cell function. Under the terms of the new agreement, Medigene will contribute expertise regarding clinical development as well as proprietary research material and has an option to an exclusive license for the clinical and/or commercial exploitation of the potential immune cell enhancers against certain fee payments.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced data from various animal studies validating the potential of Phio's INTASYL technology as a cancer immunotherapy platform for developing novel compounds. The preclinical findings, which will be presented in further detail at upcoming scientific conferences, demonstrate that the INTASYL-enabled compounds can effectively be used to reduce immunosuppression in the tumor microenvironment (TME), which is one of the key challenges for many other immunotherapy platforms to achieve an adequate therapeutic effect in solid tumors.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced the closing of its previously announced registered direct offering of 1,713,064 shares of common stock, at a purchase price of $2.335 per share, for gross proceeds of approximately $4.0 million priced at-the-market under Nasdaq rules. Phio has also issued to the investors unregistered warrants to purchase up to an aggregate of 1,713,064 shares of common stock.

\- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced the pricing of an underwritten public offering of an aggregate of 2,000,000 units at a public offering price of $4.00 per unit. Each unit contains one share of common stock (or common stock equivalent) and one warrant to purchase one share of common stock. The Company has granted the underwriter a 30-day option to purchase up to an additional 300,0000 shares of common stock and/or warrants to purchase up to 300,000 shares of common stock. The offering is expected to close on or about February 13, 2020, subject to the satisfaction of customary closing conditions.

MARLBOROUGH, Mass., Nov. 21, 2019 /PRNewswire/ -- Phio Pharmaceuticals Corp. (PHIO), a biotechnology company developing the next-generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, announced today that it expanded its research collaboration with the Karolinska Institutet in Stockholm, Sweden. The collaboration thus far has focused on the use of the Company's self-delivering RNAi compounds against targets involved in T cell and NK cell differentiation and/or tumor-induced stress response, with the aim of producing anti-tumor adoptive cell therapy grafts with improved functionality and persistence.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that it has entered into definitive agreements with several institutional investors for the purchase and sale of 1,713,064 shares of Phio's common stock, at a purchase price of $2.335 per share, for gross proceeds of approximately $4.0 million in a registered direct offering priced at-the-market under Nasdaq rules. Phio has also agreed to issue to the investors unregistered warrants to purchase up to an aggregate of 1,713,064 shares of common stock. The closing of the offering is expected to occur on or about April 2, 2020, subject to the satisfaction of customary closing conditions.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today reported its financial results for the full year ended December 31, 2019 and provided a business update.

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 11) AbbVie Inc (NYSE: ABBV ) Acceleron Pharma Inc (NASDAQ: ...

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that it has received a letter from The Nasdaq Stock Market LLC advising the Company that it has regained compliance with Nasdaq's minimum bid price listing requirement.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced data analyzing the applicability of the INTASYL platform as a gene silencing technology that offers an alternative or complementary approach to gene editing technologies, such as CRISPR / Cas9, in the treatment of solid tumors. These data will be presented today at 5:30 p.m. ET at the 23rd Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT) in virtual format. The Phio poster presentation will also be available under the "Investors – Events and Presentations" section of the Company's website (click here) approximately one hour after the event.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that the Company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-55. The reverse stock split will become effective at 12:01 a.m. Eastern Time on January 15, 2020 and the Company's common stock will open for trading on The Nasdaq Capital Market on a post-split basis on January 15, 2020 under the Company's existing trading symbol, "PHIO." At such time, the Company's common stock will also commence trading with a new CUSIP number, 71880W303.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced the closing of its previously announced registered direct offering of 197,056 shares of common stock, at a purchase price of $8.83 per share, priced at-the-market under Nasdaq rules. Additionally, the Company issued to the investors unregistered warrants to purchase up to an aggregate of 197,056 shares of common stock.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, announced today that its 2019 Special Meeting of Stockholders, scheduled for December 12, 2019, was convened and adjourned without any business being conducted due to the fact that quorum was not achieved on the proposals to be approved. The Special Meeting will be reconvened at 9:00 a.m. (Eastern Time) at the Company's executive offices on January 10, 2020 to allow more opportunity for stockholders to vote on all proposals described in the Company's definitive proxy statement filed with the Securities and Exchange Commission (SEC) on November 22, 2019.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 197,056 shares of the Company's common stock, at a purchase price of $8.83 per share, in a registered direct offering priced at-the-market under Nasdaq rules, for gross proceeds of approximately $1.74 million. The Company has also agreed to issue to the investors unregistered warrants to purchase up to an aggregate of 197,056 shares of common stock. The closing of the offering is expected to occur on or about February 6, 2020, subject to the satisfaction of customary closing conditions.

Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 10) * Arcutis Biotherapeutics Inc (NASDAQ: ARQT) * Aytu Bioscience Inc (NASDAQ: AYTU) (announced a deal to distribute COVID-19 test) * Centogene NV (NASDAQ: CNTG) * Forty Seven Inc (NASDAQ: FTSV)Down In The Dumps(Biotech Stocks Hitting 52-week lows on March 10) * Accelerate Diagnostics Inc (NASDAQ: AXDX) * Adamas Pharmaceuticals Inc (NASDAQ: ADMS) * Adaptive Biotechnologies Corp (NASDAQ: ADPT) * ADMA Biologics Inc (NASDAQ: ADMA) * Aeglea Bio Therapeutics Inc (NASDAQ: AGLE) * AEterna Zentaris Inc. (NASDAQ: AEZS) * Affimed NV (NASDAQ: AFMD) * Akari Therapeutics PLC (NASDAQ: AKTX) * Akcea Therapeutics Inc (NASDAQ: AKCA) * Aldeyra Therapeutics Inc (NASDAQ: ALDX) * Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) * Alkermes Plc (NASDAQ: ALKS) * Allena Pharmaceuticals Inc (NASDAQ: ALNA) * ANCHIANO THERAP/S ADR (NASDAQ: ANCN) * AngioDynamics, Inc. (NASDAQ: ANGO) * ANI Pharmaceuticals Inc (NASDAQ: ANIP) * Anixa Biosciences Inc (NASDAQ: ANIX) * AnPac Bio-Medical Science Co Ltd - ADR (NASDAQ: ANPC) * Aptevo Therapeutics Inc (NASDAQ: APVO) * Aptinyx Inc (NASDAQ: APTX) * Assertio Therapeutics Inc (NASDAQ: ASRT) * Atara Biotherapeutics Inc (NASDAQ: ATRA) * Atossa Therapeutics Inc (NASDAQ: ATOS) * Autolus Therapeutics Ltd - ADR (NASDAQ: AUTL) * AxoGen, Inc Common Stock (NASDAQ: AXGN) * Axovant Gene Therapies Ltd (NASDAQ: AXGT) * Bausch Health Companies Inc (NYSE: BHC) * Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) * BENITEC BIOPHAR/S ADR (NASDAQ: BNTC) * BioLife Solutions Inc (NASDAQ: BLFS) * bluebird bio Inc (NASDAQ: BLUE) * Black Diamond Therapeutics Inc (NASDAQ: BDTX) * Capricor Therapeutics Inc (NASDAQ: CAPR) * Celcuity Inc (NASDAQ: CELC) * Cerecor Inc (NASDAQ: CERC) * Chembio Diagnostics Inc (NASDAQ: CEMI) * Eiger Biopharmaceuticals Inc (NASDAQ: EIGR) * Enochian Biosciences Inc (NASDAQ: ENOB) * Entasis Therapeutics Holdings Inc (NASDAQ: ETTX) * Eton Pharmaceuticals Inc (NASDAQ: ETON) * Evolus Inc (NASDAQ: EOLS) * Exicure Inc (NASDAQ: XCUR) * Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) * Five Prime Therapeutics Inc (NASDAQ: FPRX) * Gossamer Bio Inc (NASDAQ: GOSS) * Gritstone Oncology Inc (NASDAQ: GRTS) * GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) * Heron Therapeutics Inc (NASDAQ: HRTX) * Incyte Corporation (NASDAQ: INCY) * INmune Bio Inc (NASDAQ: INMB) * Integra Lifesciences Holdings Corp (NASDAQ: IART) * Invivo Therapeutics Holdings Corp (NASDAQ: NVIV) * Jaguar Health Inc (NASDAQ: JAGX) * Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) * Kura Oncology Inc (NASDAQ: KURA) * Lantheus Holdings Inc (NASDAQ: LNTH) * TapImmune Inc. common stock (NASDAQ: MRKR) * MediciNova, Inc. (NASDAQ: MNOV) * Meridian Bioscience, Inc. (NASDAQ: VIVO) * Misonix Inc (NASDAQ: MSON) * Moleculin Biotech Inc (NASDAQ: MBRX) * Myriad Genetics, Inc. (NASDAQ: MYGN) * Neovasc Inc (NASDAQ: NVCN) * Neurometrix Inc (NASDAQ: NURO)ccccc * Neuronetics Inc (NASDAQ: STIM) * Oncternal Therapeutics Inc (NASDAQ: ONCT) * Orchard Therapeutics PLC - ADR (NASDAQ: ORTX) * Organogenesis Holdings Inc (NASDAQ: ORGO) * Pieris Pharmaceuticals Inc (NASDAQ: PIRS) * Plus Therapeutics Inc (NASDAQ: PSTV) * Polarityte Inc (NASDAQ: PTE) * Portola Pharmaceuticals Inc (NASDAQ: PTLA) * Precigen Inc (NASDAQ: PGEN) * Precipio Inc (NASDAQ: PRPO) * Radius Health Inc (NASDAQ: RDUS) * Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) * Rubius Therapeutics Inc (NASDAQ: RUBY) * SAGE Therapeutics Inc (NASDAQ: SAGE) * Stealth BioTherapeutics Corp (NASDAQ: MITO) * Stemline Therapeutics Inc (NASDAQ: STML) * SurModics, Inc. (NASDAQ: SRDX) * Synlogic Inc (NASDAQ: SYBX) * T2 Biosystems Inc (NASDAQ: TTOO) * Tcr2 Therapeutics Inc (NASDAQ: TCRR) * Teligent Inc (NEW JERSEY) (NASDAQ: TLGT) * Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) * TFF Pharmaceuticals Inc (NASDAQ: TFFP) * TRACON Pharmaceuticals Inc (NASDAQ: TCON) * Unum Therapeutics Inc (NASDAQ: UMRX) * Vericel Corp (NASDAQ: VCEL) * X4 Pharmaceuticals Inc (NASDAQ: XFOR) * Xeris Pharmaceuticals Inc (NASDAQ: XERS) * X T L Biopharmaceuticals Ltd (NASDAQ: XTLB) * ZIOPHARM Oncology Inc. (NASDAQ: ZIOP)See Also: Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates Stocks In Focus Mallinckrodt's Global Opioid Settlement Agreement Endorsed By New York State Mallinckrodt PLC (NYSE: MNK) said the New York State Attorney General Letitia James lent support to the company's previously announced global opioid settlement, joining 47 other states and U.S. Territory Attorneys General.The State of New York and Suffolk County, together with Mallinckrodt and SpecGx LLC, have jointly filed a motion to remove the companies from the New York State opioid trial.In pre-market trading, shares were rising 13.24% to $2.48.Kamada to Work On Treatment for Severely Ill COVID-19 Patients Israeli plasma-derived biopharma Kamada Ltd. (NASDAQ: KMDA) said it plans to initiate the development of an Anti-COVID-19 polyclonal immunoglobin using is its proprietary plasma derived IgG platform technology as a potential treatment for severely ill coronavirus patients."We are working with the Israeli regulatory authorities and local medical institutions to advance our program," said Amir London, CEO of Kamada.In pre-market trading, shares were up 6.23% to $5.80.FDA Approves Bristol-Myers' Opdivo-Yervoy Combo For Liver Cancer Bristol-Myers Squibb Co's (NYSE: BMY) said the FDA approved its sBLA for Opdivo + Yervoy as a treatment option for patients with advanced hepatocellular carcinoma, previously treated with Bayer AG (OTC: BAYRY) and Onyx Pharma's Nexavar.Phio Pharma Announces Agreement to Develop Immune Enhancers Phio Pharmaceuticals Corp (NASDAQ: PHIO) has reached a new agreement with Medigene relating to its previously announced research collaboration with Helmholtz Zentrum Munchen to develop novel candidates for the use of Intasyl compounds in adoptive cell therapy to enhance immune function.The new agreement provides for Medigene contributing expertise regarding clinical development and proprietary research material. The company also has an option to an exclusive license for potential immune cell enhancers against certain fee payments.Phio shares rallied 15.30% to $3.24 in after-hours trading.NuCana's Ovarian Cancer Drug Shows Favorable Disease Control In Midstage Study NuCana PLC (NASDAQ: NCNA) announced preliminary results from part one of the Phase 2 study of single-agent Acelarin in difficult-to-treat patients with platinum-resistant ovarian cancer, which showed that out of the 45 evaluable patients, one patient achieved a complete response and two patients achieved partial responses, while 16 achieved stable disease."We are pleased with this favorable disease control rate and Acelarin's ability to achieve confirmed complete and partial responses in this very heavily pre-treated patient population," said Hugh Griffith, CEO of NuCana.Separately, the company reported fourth-quarter results showing a wider loss.View more earnings on MNKNuCana shares rose 7.25% to $7.25 in after-hours trading.Sophiris Bio Shares to Be Delisted From Nasdaq, Effective March 12 Sophiris Bio Inc (NASDAQ: SPHS), which is evaluating its topsalysin in late-stage clinical trials for urological diseases, said the Nasdaq Officer of General Counsel informed the company that the Nasdaq Hearing Panel has determined to delist its shares from the Nasdaq. Trading in the company's shares are to be suspended, effective at the open of business March 12.The company said it expects its shares to be eligible for trading on the OTC.The delisting comes in the wake of the company flouting listing standards pertaining to the minimum $2.5 million stockholder's equity requirement.The stock plummeted 39.58% to 35 cents in the after-hours trading.J&J's Lung Cancer Therapy Gets Breakthrough Designation Johnson & Johnson (NYSE: JNJ) said its Janssen unit's JNJ-61186372 has been granted Breakthrough Therapy Designation by the FDA for the treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor Exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy.Roche's Biomarker-based Screening Test For Cervical Cancer Approved by FDARoche Holdings AG Basel ADR (OTC: RHHBY) said the FDA approved its CINtec PLUS Cytology, as the first biomarker-based triage test for women whose primary cervical cancer screening results are positive for HPV using the cobas 4800 HPV Test.Altimmune Soars Despite No NewsAltimmune Inc (NASDAQ: ALT) shares were sharply higher in after-hours trading, although there was no release from the company.Earnings RA Medical Systems Inc (NYSE: RMED) reported a decline in is fourth-quarter revenues from $2 million in 2018 to $1.4 million in 2019. The net loss per share narrowed from $1.18 to 72 cents. Analysts estimated a loss of $1.15 per share.The stock plunged 39.72% to 85 cents in after-hours trading.Fulgent Genetics Inc's (NASDAQ: FLGT) fourth-quarter revenues climbed 48% year-over-year to $8.4 million and the company reported non-GAAP EPS of 4 cents, in line with the consensus estimate.The stock 4.92% to $14.50 in after-hours trading.Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) reported fourth-quarter revenues of $2.07 million in 2019 compared to no revenues a year ago. The net loss per share narrowed from 16 cents to 5 cents, while analysts estimated a loss of 7 cents per share.The stock slipped 5.21% to 91 cents in after-hours trading.Offerings Kala Pharmaceuticals Inc (NASDAQ: KALA) said it has priced its underwritten public offering of 16 million shares at $7.89 per share, for generating gross proceeds of $126.2 million. The company expects the offering to close March 13.In premarket trading Wednesday, Kala shares were adding 11.53% to $8.80.On The Radar Earnings • Xeris Pharma (before the market open) • Liquidia Technologies Inc (NASDAQ: LQDA) (before the market open) • Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) (before the market open) • INmune Bio Inc (NASDAQ: INMB) (before the market open) • Clearside Biomedical Inc (NASDAQ: CLSD) (after the close) • Calithera Biosciences Inc (NASDAQ: CALA) (after the close) • Unity Biotechnology Inc (NASDAQ: UBX) (after the close) • Navidea Biopharmaceuticals Inc (NYSE: NAVB) (after the close) • Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX) (after the close) • BioLife Solutions Inc (NASDAQ: BLFS) (after the close) • Dynavax Technologies Corporation (NASDAQ: DVAX) (after the close) • Miragen Therapeutics Inc (NASDAQ: MGEN) (after the close) • Pfenex Inc (NYSE: PFNX) (after the close) • Arcturus Therapeutics Ltd (NASDAQ: ARCT) (after the close) • Novavax, Inc. (NASDAQ: NVAX) (after the close) • Global Cord Blood Corp (NYSE: CO) (after the close)See more from Benzinga * The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index * The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues * The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, announced today that its chief executive officer, Dr. Gerrit Dispersyn, will present at Biotech Showcase™ 2020 on Monday, January 13, 2020 at 2:00 pm Pacific Time at the Hilton San Francisco Union Square. Phio will also be hosting institutional investor and partnering meetings at the LifeSci Advisors Corporate Access Event being held at the Sir Francis Drake Hotel in San Francisco from January 13-15, 2020.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced dates for new data to be presented in abstract presentations at three upcoming medical meetings, as well as a management presentation at an investor conference in Spring 2020.

By John Vandermosten, CFA NASDAQ:PHIO READ THE FULL PHIO RESEARCH REPORT Full Year 2019 Financial & Operational Update Phio Pharmaceuticals Corp. (NASDAQ:PHIO) reported full year 2019 results and filed its Form 10-K on March 26, 2020. The prior year saw substantial change with a new captain at the helm and numerous new or expanded collaborations with Glycostem Therapeutics, Helmholtz Zentrum

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced the closing of its previously announced underwritten public offering of 993,633 units at a public price of $4.00 per unit and 1,006,367 pre-funded units at a public price of $3.999 per pre-funded unit, raising gross proceeds of approximately $8.0 million, prior to deducting underwriting discounts and commissions and estimated offering expenses.